Link Between M6A Modification and Infiltration Characterization of Tumor Microenvironment in Lung Adenocarcinoma

Overview

Journal Exp Biol Med (Maywood)

Specialty Biology

Date 2024 Jan 3

PMID 38166412

Authors

Sha Yang

Ke Li

Jiqin Zhang

Jian Liu

Lin Liu

Ying Tan

Chuan Xu

Affiliations

Soon will be listed here.

Abstract

N6-methyladenosine (m6A) RNA methylation plays a pivotal role in immune responses and the onset and advancement of cancer. Nonetheless, the precise impact of m6A modification in lung adenocarcinoma (LUAD) and its associated tumor microenvironment (TME) remains to be fully elucidated. Here, we distinguished distinct m6A modification patterns within two separate LUAD cohorts using a set of 21 m6A regulators. The TME characteristics associated with these two patterns align with the immune-inflamed and immune-excluded phenotypes, respectively. We identified 2064 m6A-related genes, which were used as a basis to divide all LUAD samples into three distinct m6A gene clusters. We applied a scoring system to evaluate the m6A gene signature of the m6A modification pattern in individual patients. To authenticate the categorization significance of m6A modification patterns, we established a correlation between m6A score and TME infiltration profiling, tumor somatic mutations, and responses to immunotherapy. A high level of m6A modification may be associated with the aggressiveness and poor prognosis of LUAD. Further studies should investigate the mechanism of action of m6A regulators and m6A-related genes to improve the diagnosis and treatment of patients with LUAD.

Citing Articles

IGF2BP2 promotes lung adenocarcinoma progression by regulating LOX1 and tumor-associated neutrophils.

Qian L, Ji Z, Mei L, Zhao J Immunol Res. 2024; 73(1):16.

PMID: 39688738 DOI: 10.1007/s12026-024-09563-9.

References

Liu W, Han F, Huang Y, Chen H, Chen J, Wang D . TMEM196 hypermethylation as a novel diagnostic and prognostic biomarker for lung cancer. Mol Carcinog. 2018; 58(4):474-487. DOI: 10.1002/mc.22942. View

Niu X, Liu F, Zhou Y, Zhou Z, Zhou D, Wang T . Genome-wide DNA Methylation Analysis Reveals as a Novel Epigenetic Target for 19 Deletion Lung Adenocarcinoma with Induction Erlotinib Treatment. Clin Cancer Res. 2017; 23(17):5003-5014. DOI: 10.1158/1078-0432.CCR-16-2688. View

Lv W, Wang Y, Zhao C, Tan Y, Xiong M, Yi Y . Identification and Validation of m6A-Related lncRNA Signature as Potential Predictive Biomarkers in Breast Cancer. Front Oncol. 2021; 11:745719. PMC: 8555664. DOI: 10.3389/fonc.2021.745719. View

Luo Y, Sun X, Xiong J . Characterization of m6A Regulator-Mediated Methylation Modification Patterns and Tumor Microenvironment Infiltration in Ovarian Cancer. Front Cell Dev Biol. 2022; 9:794801. PMC: 8787330. DOI: 10.3389/fcell.2021.794801. View

Han D, Liu J, Chen C, Dong L, Liu Y, Chang R . Anti-tumour immunity controlled through mRNA mA methylation and YTHDF1 in dendritic cells. Nature. 2019; 566(7743):270-274. PMC: 6522227. DOI: 10.1038/s41586-019-0916-x. View

Bremnes R, Donnem T, Al-Saad S, Al-Shibli K, Andersen S, Sirera R . The role of tumor stroma in cancer progression and prognosis: emphasis on carcinoma-associated fibroblasts and non-small cell lung cancer. J Thorac Oncol. 2010; 6(1):209-17. DOI: 10.1097/JTO.0b013e3181f8a1bd. View

Nehme E, Rahal Z, Sinjab A, Khalil A, Chami H, Nemer G . Epigenetic Suppression of the T-box Subfamily 2 () in Human Non-Small Cell Lung Cancer. Int J Mol Sci. 2019; 20(5). PMC: 6429281. DOI: 10.3390/ijms20051159. View

Seok Y, Lee W, Park J, Kim D . Promoter Methylation is Associated with Poor Prognosis in Lung Adenocarcinoma Patients. Mol Cells. 2019; 42(2):161-165. PMC: 6399005. DOI: 10.14348/molcells.2018.0322. View

Zhang X, Shi M, Chen T, Zhang B . Characterization of the Immune Cell Infiltration Landscape in Head and Neck Squamous Cell Carcinoma to Aid Immunotherapy. Mol Ther Nucleic Acids. 2020; 22:298-309. PMC: 7522342. DOI: 10.1016/j.omtn.2020.08.030. View

10.

Leek J, Johnson W, Parker H, Jaffe A, Storey J . The sva package for removing batch effects and other unwanted variation in high-throughput experiments. Bioinformatics. 2012; 28(6):882-3. PMC: 3307112. DOI: 10.1093/bioinformatics/bts034. View

11.

Zeng C, Huang W, Li Y, Weng H . Roles of METTL3 in cancer: mechanisms and therapeutic targeting. J Hematol Oncol. 2020; 13(1):117. PMC: 7457244. DOI: 10.1186/s13045-020-00951-w. View

12.

Zhang C, Huang S, Zhuang H, Ruan S, Zhou Z, Huang K . YTHDF2 promotes the liver cancer stem cell phenotype and cancer metastasis by regulating OCT4 expression via m6A RNA methylation. Oncogene. 2020; 39(23):4507-4518. DOI: 10.1038/s41388-020-1303-7. View

13.

Givechian K, Wnuk K, Garner C, Benz S, Garban H, Rabizadeh S . Identification of an immune gene expression signature associated with favorable clinical features in Treg-enriched patient tumor samples. NPJ Genom Med. 2018; 3:14. PMC: 5998068. DOI: 10.1038/s41525-018-0054-7. View

14.

Berraondo P, Sanmamed M, Ochoa M, Etxeberria I, Aznar M, Perez-Gracia J . Cytokines in clinical cancer immunotherapy. Br J Cancer. 2018; 120(1):6-15. PMC: 6325155. DOI: 10.1038/s41416-018-0328-y. View

15.

Huang H, Weng H, Chen J . mA Modification in Coding and Non-coding RNAs: Roles and Therapeutic Implications in Cancer. Cancer Cell. 2020; 37(3):270-288. PMC: 7141420. DOI: 10.1016/j.ccell.2020.02.004. View

16.

Chen Y, Pan C, Wang X, Xu D, Ma Y, Hu J . Silencing of METTL3 effectively hinders invasion and metastasis of prostate cancer cells. Theranostics. 2021; 11(16):7640-7657. PMC: 8315076. DOI: 10.7150/thno.61178. View

17.

Du C, Lv C, Feng Y, Yu S . Activation of the KDM5A/miRNA-495/YTHDF2/m6A-MOB3B axis facilitates prostate cancer progression. J Exp Clin Cancer Res. 2020; 39(1):223. PMC: 7576758. DOI: 10.1186/s13046-020-01735-3. View

18.

Sheaffer K, Elliott E, Kaestner K . DNA Hypomethylation Contributes to Genomic Instability and Intestinal Cancer Initiation. Cancer Prev Res (Phila). 2016; 9(7):534-46. PMC: 4930698. DOI: 10.1158/1940-6207.CAPR-15-0349. View

19.

Zhang L, Lu Q, Chang C . Epigenetics in Health and Disease. Adv Exp Med Biol. 2020; 1253:3-55. DOI: 10.1007/978-981-15-3449-2_1. View

20.

Luo H, Ye M, Hu Y, Wu M, Cheng M, Zhu X . DNA methylation regulator-mediated modification patterns and tumor microenvironment characterization in glioma. Aging (Albany NY). 2022; 14(19):7824-7850. PMC: 9596205. DOI: 10.18632/aging.204291. View